EVI5L: A Potential Drug Target and Biomarker for Various Diseases

Target Name: EVI5L

NCBI ID: G115704

EVI5L

EVI5L: A Potential Drug Target and Biomarker for Various Diseases

EVI5L (EVI5-like protein (isoform 2)) is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. EVI5L is a member of the EVI5 family of proteins, which are known for their ability to interact with various cellular signaling pathways, including TGF-β, NF-kappa-B, and signaling pathways related to inflammation and cellular signaling. In this article, we will provide an overview of EVI5L, its potential drug target status , and its potential clinical applications.

Potential Drug Target Status

EVI5L has been identified as a potential drug target due to its ability to interact with various signaling pathways, including TGF-β, NF-kappa-B, and signaling pathways related to inflammation and cellular signaling. These interactions make EVI5L a potential target for small molecule inhibitors , antibodies, or other therapeutic agents that can modulate these signaling pathways.

One of the key features that make EVI5L a potential drug target is its ability to interact with multiple signaling pathways. For example, EVI5L has been shown to interact with TGF-β, which is involved in cell growth, differentiation, and regulation of cell- cell interactions. Similarly, EVI5L has also been shown to interact with NF-kappa-B, which is involved in inflammation and cellular signaling. These interactions make EVI5L a potential target for drugs that can modulate these signaling pathways, including inhibitors of tyrosine inhibitor kinases, inhibitors of nuclear factor kappa B (NF-kappa-B), or inhibitors of WeChat Pay (IMF) signaling.

Another feature that makes EVI5L a potential drug target is its ability to modulate the cellular signaling pathways that are involved in cancer progression. For example, EVI5L has been shown to interact with the transcription factor retinoblastoma gene (RB), which is involved in the regulation of cellular signaling pathways that are involved in cancer progression. These interactions make EVI5L a potential target for drugs that can modulate RB signaling, including inhibitors of retinoblastoma gene inhibitors (RBGIs), which are drugs that can inhibit the activity of RB, including inhibitors of its downstream signaling pathways.

Potential Clinical Applications

EVI5L is a protein that has the potential to be used in a variety of clinical applications, including cancer, neurodegenerative diseases, and autoimmune disorders.

In the context of cancer, EVI5L has been shown to be involved in the regulation of cellular signaling pathways that are involved in cancer progression. For example, EVI5L has been shown to interact with the transcription factor retinoblastoma gene (RB), which is involved in the regulation of cellular signaling pathways that are involved in cancer progression. These interactions make EVI5L a potential target for drugs that can modulate RB signaling, including inhibitors of retinoblastoma gene inhibitors (RBGIs), which are drugs that can inhibit the activity of RB, including inhibitors of its downstream signaling pathways.

In the context of neurodegenerative diseases, EVI5L has been shown to be involved in the regulation of cellular signaling pathways that are involved in neurodegeneration. For example, EVI5L has been shown to interact with the neurotransmitter serotonin, which is involved in neurotransmission and regulation of mood , anxiety, and pain. These interactions make EVI5L a potential target for drugs that can modulate serotonin signaling pathways, including inhibitors of 5-HT reuptake inhibitors (5-HTRIs), which are drugs that can inhibit the action of serotonin reuptake, including fluoxetine (FLU) and duloxetine (DULOX), which are commonly used to treat

Protein Name: Ecotropic Viral Integration Site 5 Like

Functions: Functions as a GTPase-activating protein (GAP) with a broad specificity

The "EVI5L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EVI5L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets